Vaccines Market Outlook To 2024: Key Product Categories (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, DNA Vaccines), Disease Type, End-Use, Regional Segmentation, Competitive Dynamics, M&A Insights, Pricing Analysis (OPP, IPP, RAP), And Segment Forecast

$3,650.00$6,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The global vaccines market was valued at $32 bn in 2016 and is anticipated to reach $61.6 bn by 2024.

 

The vaccines market is expected to grow owing to factors such as rise in prevalence of chronic diseases, growing healthcare expenditure, improvement in access to healthcare, high investment in R&D, increasing support from government and stakeholders such as UNICEF, WHO (World Health Organization), PAHO (Pan-American Healthcare Organisation) and others. The rise in prevalence of tuberculosis, influenza, rotavirus infection, polio, measles and other diseases is a major concern for governments across the developed and emerging nations.

 

The increasing healthcare expenditure to support the treatment of millions of patients suffering from various diseases is a key challenge for the healthcare providers, payers, and governments. In 2014, the Ebola outbreak in western Africa was declared as a Public Health Emergency of International Concern under the WHO International Health Regulations (2005). As per estimates by WHO, the number of Ebola cases reported in Sierra Leone were 14,124, Guinea-3,811 cases, Liberia-10,675 cases.

 

To resolve the crisis and prevent future disasters, nearly 2 million doses of three candidate vaccines were manufactured by companies such as GlaxoSmithKline, Johnson & Johnson, and Merck. It is estimated that more than 20,000 people were vaccinated in 2014-15. Furthermore, GAVI Vaccine Alliance and Merck Sharp & Dohme Corporation have entered into a USD 5 million advance purchase agreement to support the development of Ebola vaccine stockpile. These drugs have not received the U.S. FDA, and EMEA approval, and are presently procured by countries to conduct clinical studies and treat the affected patients.

 

Vaccine Market 2024

 

The U.S. spends the highest dollars toward healthcare expenses 17nditure, each year. At present, it allocates 17% of GDP which equals to USD 3.2 trillion and the required budget is increasing each year due to multiple economic, social and healthcare factors. It has one of the highest immunization rates for different diseases, and the data is presented below,

 

Vaccines Market Share

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Vaccines”

 

Estimated Average vaccine cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Pricing is a key factor impacting the market dynamics across different regions. The high-income countries due to the high healthcare expenditure can afford the technologically advanced products. However, the low-income and developing nations cannot procure the high-end products. The introduction of generic versions is crucial to meet the growing demand for vaccines across these countries. The pricing power is skewed toward large purchase organizations such as UNICEF and PAHO, which negotiate and procure vaccines for supplying in more than 100 countries. In the U.S., the CDC procures vaccines at a discounted rate for its immunization programs across different states.

 

Product Outlook

 

Based on product, the market is segmented as live attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, DNA vaccines. The inactivated vaccines contain the antigenic part of the pathogen which is required to elicit an immune response. This segment is expected to continue its dominance over the forecast period due to advantages such as long shelf life and high stability.

 

The DNA vaccine segment is expected to register the maximum CAGR over the forecast period. The technology includes the extraction of genetic material from the specific disease-causing pathogen and introducing it into human cells. The DNA vaccines provide protection against a host of parasitic, fungal, bacterial and viral infections. Furthermore, the strong pipeline in this category is anticipated to propel the usage rates over the forecast period.

 

Disease and End-Use Outlook

 

Based on the type of disease, the market is categorized into the meningococcal disease, pneumococcal disease, tetanus, hepatitis, measles, mumps, and rubella (MMR), rotavirus, varicella, human papilloma virus (HPV) infection, polio, diphtheria, pertussis (DTP) and others. The pneumococcal disease category accounted for the largest revenue share due to the high incidence rate and growing government initiatives to improve the immunization programs.

 

Based on end use, the market is segmented into adults and pediatrics. The pediatrics segment accounts for the maximum share and is expected to be the fastest-growing category over the forecast period. The vaccination at a young age builds the immunity against these diseases. For instance, polio vaccination is given 4 doses of IPV at age 2 months, 4 months, 6 to 18 months, which is followed by a booster dose at the age of 4 to 6 years.

 

Regional Segmentation

 

North America accounted for the maximum share, followed by Europe and Asia Pacific. The global vaccines market is dominated by the high-income countries due to their high healthcare expenditure on healthcare infrastructure, community development, research & development, and vaccination programs for different diseases. As per WHO estimates, the high-income countries in North America and Europe account for nearly 82% of the global vaccine sales by revenue and 20% by volume. These regions spend significantly on manufacturing and importing the most advanced vaccines and pay a higher premium for the products compared to other regions. In North America, U.S. dominates the regional market due to a high incidence rate of diseases, high focus on research & development and constant efforts by the government to provide the best healthcare services to its citizens.

 

Asia Pacific is expected to emerge as the fastest growing region due to increasing government efforts in providing vaccination to its citizens. The high prevalence of various diseases in the region is driving the increase in healthcare expenditure and improvement in access to basic healthcare facilities. The governments in coordination with agencies such as WHO, UNICEF are actively working toward eliminating the threat of infectious diseases by conducting extensive vaccination programs.

 

Merger & Acquisition Insight

 

The vaccines market in the recent past has witnessed several high value transactions and the market has a huge scope for consolidation. Some of the most notable transactions in recent times include the GSK and Novartis portfolio swap in 2015. In 2017, Serum Institute of India Pvt. Ltd., has acquired Nanotherapeutics, which has made it as the largest injectable polio vaccine in the world

 

Top Players & Company Share

 

Key players operating in the market include GlaxoSmithKline, plc., Novartis AG, Emergent BioSolutions, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc, Takeda Pharmaceuticals Company Ltd., Valeant Pharmaceuticals International, Inc., Astellas Pharma Inc. and others

 

Market Segmentation

 

Vaccines Market by Product (Revenue, Million, 2014 – 2024)

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Conjugate Vaccines
  • DNA Vaccines

Vaccines Market by Disease Type, Revenue, USD Million, 2014 – 2024)

  • Pneumococcal
  • Influenza
  • HPV
  • Hepatitis
  • Rotavirus
  • Vaccination
  • DTP
  • Polio
  • MMR
  • Varicella
  • Others

Vaccines Market by End-Use (Revenue, USD Million, 2014 – 2024)

  • Adults
  • Pediatrics

Vaccines Market Regional Outlook (Revenue, USD Million, 20124- 2024)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Vaccines Market Overview

  • Global Disease Landscape
  • Global Healthcare Expenditure

Chapter 4 Vaccines Industry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Key Market Drivers
    • Rising Prevalence of Chronic Diseases
    • Increasing Geriatric Population
    • Government support for research and development
  • Key Market Challenges
    • Affordability and access to healthcare services
    • Lack of storage and supply chain infrastructure
  • Key Opportunities Prioritized
  • Industry Analysis - Porter’s
  • Vaccines Market-PESTEL Analysis

Chapter 5: - Product Type Market Outlook

Vaccines Market Landscape by Technology Type- 2016 & 2024
  • Conjugate Vaccines
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Inactivated and Subunit Vaccines
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Live Attenuated Vaccines
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Toxoid Vaccines
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Recombinant Vaccines
    • Market Landscape Analysis, 2016-2024 (USD Mn)
 

Chapter 6: -Disease Type Market Outlook

Vaccines Market Landscape by Disease Type- 2016 & 2024
  • DTP
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Influenza
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Pneumococcal Disease
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Human Papilloma Virus
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Human Papilloma Virus
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Meningococcal Disease
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Polio
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Rotavirus
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Hepatitis
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Polio
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • MMR
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Varicella
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Others
    • Market Landscape Analysis, 2016-2024 (USD Mn)

Chapter 7: -End-Use Market Outlook

Vaccines Market Landscape by End-Use- 2016 & 2024
  • Adults
    • Market Landscape Analysis, 2016-2024 (USD Mn)
  • Pediatrics
    • Market Landscape Analysis, 2016-2024 (USD Mn)

Chapter 8: Regional Market Outlook

Vaccines Market Landscape by Region- 2016
  • North America Market Landscape Analysis, 2016-2024 (USD Mn)
    • US. Market Landscape Analysis, 2016-2024
    • Canada Market Landscape Analysis-2016-2024
  • Europe Market Landscape Analysis, 2016-2024 (USD Mn)
    • UK Market Landscape Analysis, 2016-2024
    • Germany Market Landscape Analysis, 2016-2024
    • France Market Landscape Analysis, 2016-2024
    • Italy Market Landscape Analysis, 2016-2024
    • Spain Market Landscape Analysis, 2016-2024
  • Latin America Market Landscape Analysis, 2016-2024 (USD Mn)
    • Brazil Market Landscape Analysis, 2016-2024
    • Mexico Market Landscape Analysis, 2016-2024
    • Colombia Market Landscape Analysis, 2016-2024
  • Asia pacific Market Landscape Analysis, 2016-2024 (USD Mn)
    • Japan Market Landscape Analysis, 2016-2024
    • China Market Landscape Analysis, 2016-2024
    • India Market Landscape Analysis, 2016-2024
  • Middle East & Africa Market Landscape Analysis, 2014-2024 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2014-2024
    • South Africa Market Landscape Analysis, 2014-2024
 

Chapter 9: Pricing Analysis

Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2016
  • North America Pricing Analysis (OPP, IPP, and RAP - 2016)
    • U.S. Pricing Analysis-2016
    • Canada Pricing Analysis-2016
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2016)
    • UK Pricing Analysis-2016
    • Germany Pricing Analysis-2016
    • France Pricing Analysis-2016
    • Italy Pricing Analysis-2016
    • Spain Pricing Analysis-2016
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2016)
    • Brazil Pricing Analysis-2016
    • Mexico Pricing Analysis-2016
    • Colombia Pricing Analysis-2016
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2016)
    • Japan Pricing Analysis-2016
    • China Pricing Analysis-2016
    • India Pricing Analysis-2016
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2016)
    • Saudi Arabia Pricing Analysis-2016
    • South Africa Pricing Analysis-2016

Chapter 10: Vaccines Pipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 11: Vaccines Merger &Acquisition Outlook

  • Factors driving M&A in smart syringes market
  • Key trends and future outlook

Chapter 12: Competitive Landscape

  • Glaxosmithkline, PLC.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Merck & Co., Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Sanofi Pasteur
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Pfizer, Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Emergent Biosolutions, Inc
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Johnson & Johnson
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Medimmune, LLC.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Astellas Pharma Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Serum Institute of India
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Novartis AG.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Valeant Pharmaceuticals International
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Astellas Pharma Inc
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  List of Tables  
  • TABLE 1 Vaccines Market - Industry Snapshot & Key Buying Criteria, 2014 - 2024
  • TABLE 2 Global Vaccines Market, 2014 – 2024
  • TABLE 3 Global Vaccines Market Analysis by Product -2016
  • TABLE 4 Global Vaccines Market Analysis by Disease Type-2016
  • TABLE 5 Global Vaccines Market Analysis by End Use -2016
  • TABLE 7 Global Vaccines Market Analysis by Geography-2016
  • TABLE 8 Global Vaccines Market Analysis by Leading Brands-2016
  • TABLE 9 Vaccines Market - Key market driver analysis
  • TABLE 10 Vaccines Market - Key market restraint analysis
  • TABLE 11 North America Market Vaccines Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 12U.S. Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 13 Canada Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 14 Europe Vaccines Market Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 15 U.K Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 16 Germany Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 17 France Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 18 Italy Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 19 Spain Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 20 Latin America Vaccines Market Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 21 Brazil Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 22 Mexico Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 20 Colombia Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 21 Asia pacific Vaccines Market Landscape Analysis, 2016-2024 (USD Mn)
  • TABLE 22 Japan Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 23 China Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 24 India Vaccines Market Landscape Analysis, 2016-2024
  • TABLE 25 North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 27 U.S. Pricing Analysis-2016
  • TABLE 28 Canada Pricing Analysis-2016
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 30 U.K Pricing Analysis-2016
  • TABLE 31 Germany Pricing Analysis-2016
  • TABLE 32 France Pricing Analysis-2016
  • TABLE 33 Italy Pricing Analysis-2016
  • TABLE 34 Spain Pricing Analysis-2016
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 36 Brazil Pricing Analysis-2016
  • TABLE 37 Mexico Pricing Analysis-2016
  • TABLE 38 Colombia Pricing Analysis-2016
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 40 Japan Pricing Analysis-2016
  • TABLE 41 China Pricing Analysis-2016
  • TABLE 42 India Pricing Analysis-2016
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2016)
  • TABLE 44 Saudi Arabia Pricing Analysis-2016
  • TABLE 45 South Africa Pricing Analysis-2016
  List of Figures  
  • 1 Vaccines Market Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Vaccines Market – PESTEL Analysis
  • 7 Vaccines Market Share by Product Type, 2016 & 2024
  • 8 Vaccines Market Share by Technology Type, 2016 & 2024
  • 9 Vaccines Market Share by Disease Type, 2016 & 2024
  • 10 Vaccines Market Share by End-Use, 2016 & 2024

Key Insights Addressed:  

  • Defining market size from 2014 to 2016.
  • Estimating market growth till 2024 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of the competitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:    
  • The global vaccines market was valued at $32bn in 2016 and is anticipated to reach $61.6bn. by 2024.
  • As per estimates by WHO, the number of Ebola cases reported in Sierra Leone were 14,124, Guinea-3,811 cases, Liberia-10,675 cases. To resolve the crisis and prevent future disasters, nearly 2 million doses of three candidate vaccines were manufactured by companies such as GlaxoSmithKline, Johnson & Johnson, and Merck.
  • The pricing power is skewed toward large purchase organizations such as UNICEF and PAHO, which negotiate and procure vaccines for supplying in more than 100 countries.
  • Key players operating in the market include GlaxoSmithKline, plc., Novartis AG, Emergent BioSolutions, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc, Takeda Pharmaceuticals Company Ltd., Valeant Pharmaceuticals International, Inc., Astellas Pharma Inc. and others

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involves in the process are as below-

  1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
  2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
  3. Need Gap Analysis- Defining the gap between our scope and availability of information.
  4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
  5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
  6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
  7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The global vaccines market was valued at $32 bn in 2016 and is anticipated to reach $61.6 bn by 2024.

 

The vaccines market is expected to grow owing to factors such as rise in prevalence of chronic diseases, growing healthcare expenditure, improvement in access to healthcare, high investment in R&D, increasing support from government and stakeholders such as UNICEF, WHO (World Health Organization), PAHO (Pan-American Healthcare Organisation) and others. The rise in prevalence of tuberculosis, influenza, rotavirus infection, polio, measles and other diseases is a major concern for governments across the developed and emerging nations.

 

The increasing healthcare expenditure to support the treatment of millions of patients suffering from various diseases is a key challenge for the healthcare providers, payers, and governments. In 2014, the Ebola outbreak in western Africa was declared as a Public Health Emergency of International Concern under the WHO International Health Regulations (2005). As per estimates by WHO, the number of Ebola cases reported in Sierra Leone were 14,124, Guinea-3,811 cases, Liberia-10,675 cases.

 

To resolve the crisis and prevent future disasters, nearly 2 million doses of three candidate vaccines were manufactured by companies such as GlaxoSmithKline, Johnson & Johnson, and Merck. It is estimated that more than 20,000 people were vaccinated in 2014-15. Furthermore, GAVI Vaccine Alliance and Merck Sharp & Dohme Corporation have entered into a USD 5 million advance purchase agreement to support the development of Ebola vaccine stockpile. These drugs have not received the U.S. FDA, and EMEA approval, and are presently procured by countries to conduct clinical studies and treat the affected patients.

 

Vaccine Market 2024

 

The U.S. spends the highest dollars toward healthcare expenses 17nditure, each year. At present, it allocates 17% of GDP which equals to USD 3.2 trillion and the required budget is increasing each year due to multiple economic, social and healthcare factors. It has one of the highest immunization rates for different diseases, and the data is presented below,

 

Vaccines Market Share

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Vaccines”

 

Estimated Average vaccine cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Pricing is a key factor impacting the market dynamics across different regions. The high-income countries due to the high healthcare expenditure can afford the technologically advanced products. However, the low-income and developing nations cannot procure the high-end products. The introduction of generic versions is crucial to meet the growing demand for vaccines across these countries. The pricing power is skewed toward large purchase organizations such as UNICEF and PAHO, which negotiate and procure vaccines for supplying in more than 100 countries. In the U.S., the CDC procures vaccines at a discounted rate for its immunization programs across different states.

 

Product Outlook

 

Based on product, the market is segmented as live attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, DNA vaccines. The inactivated vaccines contain the antigenic part of the pathogen which is required to elicit an immune response. This segment is expected to continue its dominance over the forecast period due to advantages such as long shelf life and high stability.

 

The DNA vaccine segment is expected to register the maximum CAGR over the forecast period. The technology includes the extraction of genetic material from the specific disease-causing pathogen and introducing it into human cells. The DNA vaccines provide protection against a host of parasitic, fungal, bacterial and viral infections. Furthermore, the strong pipeline in this category is anticipated to propel the usage rates over the forecast period.

 

Disease and End-Use Outlook

 

Based on the type of disease, the market is categorized into the meningococcal disease, pneumococcal disease, tetanus, hepatitis, measles, mumps, and rubella (MMR), rotavirus, varicella, human papilloma virus (HPV) infection, polio, diphtheria, pertussis (DTP) and others. The pneumococcal disease category accounted for the largest revenue share due to the high incidence rate and growing government initiatives to improve the immunization programs.

 

Based on end use, the market is segmented into adults and pediatrics. The pediatrics segment accounts for the maximum share and is expected to be the fastest-growing category over the forecast period. The vaccination at a young age builds the immunity against these diseases. For instance, polio vaccination is given 4 doses of IPV at age 2 months, 4 months, 6 to 18 months, which is followed by a booster dose at the age of 4 to 6 years.

 

Regional Segmentation

 

North America accounted for the maximum share, followed by Europe and Asia Pacific. The global vaccines market is dominated by the high-income countries due to their high healthcare expenditure on healthcare infrastructure, community development, research & development, and vaccination programs for different diseases. As per WHO estimates, the high-income countries in North America and Europe account for nearly 82% of the global vaccine sales by revenue and 20% by volume. These regions spend significantly on manufacturing and importing the most advanced vaccines and pay a higher premium for the products compared to other regions. In North America, U.S. dominates the regional market due to a high incidence rate of diseases, high focus on research & development and constant efforts by the government to provide the best healthcare services to its citizens.

 

Asia Pacific is expected to emerge as the fastest growing region due to increasing government efforts in providing vaccination to its citizens. The high prevalence of various diseases in the region is driving the increase in healthcare expenditure and improvement in access to basic healthcare facilities. The governments in coordination with agencies such as WHO, UNICEF are actively working toward eliminating the threat of infectious diseases by conducting extensive vaccination programs.

 

Merger & Acquisition Insight

 

The vaccines market in the recent past has witnessed several high value transactions and the market has a huge scope for consolidation. Some of the most notable transactions in recent times include the GSK and Novartis portfolio swap in 2015. In 2017, Serum Institute of India Pvt. Ltd., has acquired Nanotherapeutics, which has made it as the largest injectable polio vaccine in the world

 

Top Players & Company Share

 

Key players operating in the market include GlaxoSmithKline, plc., Novartis AG, Emergent BioSolutions, Inc., Sanofi Pasteur, Inc., AstraZeneca Plc, Takeda Pharmaceuticals Company Ltd., Valeant Pharmaceuticals International, Inc., Astellas Pharma Inc. and others

 

Market Segmentation

 

Vaccines Market by Product (Revenue, Million, 2014 – 2024)

  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • Conjugate Vaccines
  • DNA Vaccines

Vaccines Market by Disease Type, Revenue, USD Million, 2014 – 2024)

  • Pneumococcal
  • Influenza
  • HPV
  • Hepatitis
  • Rotavirus
  • Vaccination
  • DTP
  • Polio
  • MMR
  • Varicella
  • Others

Vaccines Market by End-Use (Revenue, USD Million, 2014 – 2024)

  • Adults
  • Pediatrics

Vaccines Market Regional Outlook (Revenue, USD Million, 20124- 2024)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

Additional information

Price

Single User $3,650, Multiple User $4,650, Enterprise User $6,650